Malignant Neoplastic Disease clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 18 years and up
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
at UC Irvine UCSD